Present role and future prospects of positron emission tomography in clinical oncology

Positron emission tomography (PET) has emerged as a significant molecular imaging technique in clinical oncology and cancer research. PET with 18F‐fluorodeoxyglucose (18F‐FDG) demonstrates elevated glucose consumption by tumor cells, and is used clinically for the accurate staging and restaging of cancer, planning of radiotherapy, and predicting response or lack of response in the early stages of treatment. Combined PET and computed tomography (PET‐CT) provides both functional and morphological information of the disease to allow accurate diagnosis of cancer. PET with new radiotracers such as protein synthesis markers and proliferation markers, as well as hypoxia and receptor‐binding agents, will offer patient‐specific images in order to yield tailored diagnostic and prognostic information. (Cancer Sci 2006; 97: 1291–1297)

[1]  R. Hawkins,et al.  Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy. , 1993, International journal of radiation oncology, biology, physics.

[2]  H. Kuwano,et al.  Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma , 2004, The British journal of surgery.

[3]  K Kubota,et al.  From tumor biology to clinical PET: A review of positron emission tomography (PET) in oncology , 2001, Annals of nuclear medicine.

[4]  K L Lindsley,et al.  Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. , 1995, International journal of radiation oncology, biology, physics.

[5]  J. Eary,et al.  [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Y Yonekura,et al.  Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  M. Schwaiger,et al.  Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  R. Cerfolio,et al.  The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. , 2005, The Journal of thoracic and cardiovascular surgery.

[9]  Michael J. Welch,et al.  Positron emission tomographic assessment of ”metabolic flare” to predict response of metastatic breast cancer to antiestrogen therapy , 1999, European Journal of Nuclear Medicine.

[10]  Elisabeth Kjellén,et al.  FDG PET studies during treatment: Prediction of therapy outcome in head and neck squamous cell carcinoma , 2002, Head and Neck.

[11]  Mark Muzi,et al.  In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  Otto Muzik,et al.  Imaging proliferation in vivo with [F-18]FLT and positron emission tomography , 1998, Nature Medicine.

[13]  Ora Israel,et al.  Is 18F-FDG PET/CT useful for imaging and management of patients with suspected occult recurrence of cancer? , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  F Shishido,et al.  Cerebral glioma: evaluation with methionine PET. , 1993, Radiology.

[15]  T. Higuchi,et al.  Comparison of 11C-choline PET and FDG PET for the differential diagnosis of malignant tumors , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  Michael E Phelps,et al.  Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  P F Sharp,et al.  Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Leonard,et al.  PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  J. Buatti,et al.  Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: a preliminary report. , 2004, International journal of radiation oncology, biology, physics.

[20]  Paul J. van Diest,et al.  Biologic correlates of 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography , 2002 .

[21]  M. Schwaiger,et al.  Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Bading,et al.  Pharmacokinetics of the thymidine analog 2'-fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (FMAU) in tumor-bearing rats. , 2004, Nuclear medicine and biology.

[23]  A. Luxen,et al.  Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  A. Alavi,et al.  Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma? , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  J. Vose,et al.  Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  L. Weih,et al.  Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer , 2005, Head & neck.

[27]  M. Schwaiger,et al.  Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Nährig,et al.  Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Otto S Hoekstra,et al.  Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy--systematic review. , 2005, Radiology.

[30]  T. Jones,et al.  Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group. , 1995, European journal of cancer.

[31]  C Clifton Ling,et al.  Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor mo , 2005, International journal of radiation oncology, biology, physics.

[32]  J. Pruim,et al.  Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[1-11C]tyrosine PET. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  R Iwata,et al.  Differential diagnosis of lung tumor with positron emission tomography: a prospective study. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  K Endo,et al.  In vivo comparison of PET and SPECT radiopharmaceuticals in detecting breast cancer. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  T. Higuchi,et al.  Positron emission tomographic imaging with11C-choline in differential diagnosis of head and neck tumors: comparison with18F-FDG PET , 2004, Annals of nuclear medicine.

[36]  G. V. von Schulthess,et al.  Fluorocholine PET/CT in patients with prostate cancer: initial experience. , 2005, Radiology.

[37]  Ora Israel,et al.  Cancer Recurrence: Diagnostic Value and Impact on Patient Management , 2004 .

[38]  P. Dupont,et al.  Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  G. van Kaick,et al.  Fluorine-18-fluorouracil to predict therapy response in liver metastases from colorectal carcinoma. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[40]  J. Nährig,et al.  Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  D. Noh,et al.  Fluorodeoxyglucose positron emission tomography for detection of recurrent or metastatic breast cancer , 2001, World Journal of Surgery.

[42]  J Aoki,et al.  Detection of malignant tumors: whole-body PET with fluorine 18 alpha-methyl tyrosine versus FDG--preliminary study. , 2001, Radiology.

[43]  Torsten Mattfeldt,et al.  3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. , 2002, Cancer research.

[44]  金子 文成,et al.  長時間歩行時の下肢筋の活動状態:[ 18 F]fluorodeoxyglucoseを用いたPositron Emission Tomographyによる検討 , 2008 .

[45]  M. Welch,et al.  Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  E. Aboagye,et al.  Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. , 2005, Cancer research.

[47]  A. Shields,et al.  Synthesis of 2'-deoxy-2'-[18F]fluoro-beta-D-arabinofuranosyl nucleosides, [18F]FAU, [18F]FMAU, [18F]FBAU and [18F]FIAU, as potential PET agents for imaging cellular proliferation. Synthesis of [18F]labelled FAU, FMAU, FBAU, FIAU. , 2003, Nuclear medicine and biology.

[48]  R. Fisher,et al.  Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  A. Figer,et al.  Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. , 2004, Radiology.

[50]  S. Alyafei,et al.  Metabolic studies of [18F-alpha-methyl]tyrosine in mice bearing colorectal carcinoma LS-180. , 1999, Anti-cancer drugs.

[51]  T. Hickish,et al.  Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  Y. Erdi,et al.  Tumor Localization of 16β-18F-Fluoro-5α-Dihydrotestosterone Versus 18F-FDG in Patients with Progressive, Metastatic Prostate Cancer , 2004 .

[53]  Mark A Mintun,et al.  Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. , 2003, International journal of radiation oncology, biology, physics.

[54]  H. Tsujii,et al.  Usefulness of PET with 11C-methionine for the detection of hilar and mediastinal lymph node metastasis in lung cancer. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[55]  Lutz Tellmann,et al.  Comparison of O-(2-18F-fluoroethyl)-L-tyrosine PET and 3-123I-iodo-alpha-methyl-L-tyrosine SPECT in brain tumors. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[56]  P. V. van Diest,et al.  Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  I. Weinberg,et al.  Preparation of F-18 labeled annexin V: a potential PET radiopharmaceutical for imaging cell death. , 2004, Nuclear medicine and biology.

[58]  T. Hara,et al.  PET imaging of prostate cancer using carbon-11-choline. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.